[{"data":1,"prerenderedAt":184},["ShallowReactive",2],{"content-route-/en/research/coconut-oil-denture-stomatitis-trial-2023":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":166,"alternates":175},"target","/en/research/coconut-oil-denture-stomatitis-trial-2023","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":66,"body":70},"Coconut oil for denture stomatitis: 2023 trial","A small 14-day trial compared virgin coconut oil with chlorhexidine in adults 60+; the results do not establish that one treatment was better.","2026-10-09","Drafted a study-specific summary of the 2023 VCO trial; no clinical claim or practical action changed.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":42,"limitations":49,"practicalChange":65},"lee-munoz-mcfa-denture-stomatitis-2023","Randomized, controlled, parallel-group trial described by the authors as triple-blind","Self-reliant adults aged 60 or older with removable dentures and Newton type I or II denture stomatitis; participants were healthy or had medically controlled chronic conditions.","43 participants were randomized (21 to CHX and 22 to VCO); 33 were analyzed (15 CHX and 18 VCO). The authors invited 621 older adults through one municipality near the University of Chile Faculty of Dentistry.","contextual","This small, 14-day human trial is a bounded comparison of VCO with 0.12% CHX for diagnosed Newton type I or II denture stomatitis in self-reliant adults aged 60 or older. The end-of-study clinical counts and within-group changes do not establish that VCO was superior to CHX, and salivary Candida counts did not significantly decrease from baseline to the end in either group. Attrition, unexplained T1 denominators, and unreported adverse events further limit the interpretation. It adds context to a specific local condition but does not change broader Candida conclusions or practical guidance.","/en/research/evidence/broad-candida-claims","Funded by grant FONIS SA19I0025 from the Chilean National Research and Development Agency (ANID), Government of Chile.","The authors declared no competing interests.","2023-05-29",[38,39,40,41],"Forty-three participants were randomized (21 to CHX and 22 to VCO), but only 33 were analyzed after 10 did not complete treatment: 15 in the CHX group and 18 in the VCO group. The paper says these participants were not considered in the analysis despite describing the study as intention-to-treat.","Participants used 0.12% CHX (15 mL) or about 5 g of VCO twice daily for 14 days, rinsing for five minutes each time. At the end, 5/15 CHX participants and 9/18 VCO participants were classified as healthy, compared with 0/15 and 0/18 at baseline. Within-arm severity tests showed T0-to-T2 changes (CHX p=.014; VCO p=.002), but these tests do not establish between-arm superiority. The authors reported a slight association between treatment and remission without a statistically significant difference. The T1 table totals were 13 for CHX and 16 for VCO, with no explanation of which visits were missing.","Median salivary Candida-compatible counts (CFU/mL) changed from 261.5 (range 0–58,400) to 779 (0–21,640) for CHX and from 631 (0–52,400) to 50 (0–81,800) for VCO between T0 and T2. Neither baseline-to-end change was statistically significant (CHX p=.092; VCO p=.974). The study counted colonies compatible with Candida in saliva; it did not identify species.","The article did not report an adverse-event assessment method or adverse-event results, so it provides no information about whether adverse events occurred.",{"appliesTo":43,"doesNotApplyTo":45},[44],"The 33 analyzed, self-reliant adults aged 60 or older with removable dentures and clinically classified Newton type I or II denture stomatitis, treated for 14 days with VCO or 0.12% CHX alongside denture-hygiene instructions.",[46,47,48],"People younger than 60, people with Newton type III disease, severe dependence or institutionalization, or people without removable dentures; these groups were not represented in the analyzed study population.","General oral thrush, Candida symptoms elsewhere in the body, broad Candida explanations, or consumer products claimed to disrupt biofilms.","A recommendation to use coconut oil, proof that VCO is more effective than CHX, or evidence of biofilm disruption; the trial did not measure biofilm.",[50,53,56,59,62],{"finding":51,"limitation":52},"10 of 43 randomized participants did not complete treatment and were excluded from analysis; the analyzed sample was 15/21 in CHX and 18/22 in VCO.","The paper provides no participant-level account of these exclusions or arm-specific reasons and handling of missing outcomes, despite describing the analysis as intention-to-treat.",{"finding":54,"limitation":55},"At the end of treatment, 9/18 VCO participants and 5/15 CHX participants were classified as healthy, and both groups had within-arm severity changes from T0 to T2.","The authors reported a slight association between treatment and remission without a statistically significant difference. Within-arm tests (VCO p=.002; CHX p=.014) do not establish superiority or noninferiority; no confidence interval for the remission comparison was reported.",{"finding":57,"limitation":58},"The T1 severity tables total 13 CHX participants and 16 VCO participants, below the analyzed totals of 15 and 18.","The article does not explain which participants lacked T1 data or why.",{"finding":60,"limitation":61},"The end-of-treatment salivary Candida count was not significantly lower than baseline in either group; adverse-event results were not reported.","Counts were based on colonies compatible with Candida in saliva, not species-level identification or a palatal/prosthesis-site sample. The study did not measure biofilm, and unreported adverse events cannot be treated as absent.",{"finding":63,"limitation":64},"Recruitment came from one municipality; the final analyzed sample was small and included 32 women and 1 man.","Results have limited generalizability. Participants were self-reliant adults aged at least 60 with Newton type I or II disease, and treatment lasted 14 days. The abstract calls the final assessment day 15 while the Methods section calls it day 14; the article does not resolve the wording difference. Although authors describe triple blinding, they do not explain how masking worked for visibly different rinses.","No practical change. This trial does not support recommending coconut oil or changing care for general oral thrush, broader Candida claims, or biofilm-related products.",[67],{"group":68,"route":33,"label":69},"evidence","Broad Candida claims evidence map",{"type":71,"value":72,"toc":162},"minimark",[73,81,87,93,99,114,120,126,132,138,144],[74,75,77],"content-section",{"section-key":10,"title":76},"Bottom line",[78,79,80],"p",{},"A small randomized trial in self-reliant adults aged 60 or older with Newton type I or II denture stomatitis compared virgin coconut oil (VCO) with 0.12% chlorhexidine (CHX) for 14 days. At the end, 9/18 people in the VCO group and 5/15 in the CHX group were classified as healthy. Within-group improvement does not establish that VCO was better than CHX, and 10 of 43 randomized participants were excluded from analysis. Salivary Candida counts did not significantly decrease from baseline to the end in either group. Adverse events were not reported. The trial does not support recommending coconut oil or changing broader Candida guidance.",[74,82,84],{"section-key":11,"title":83},"Why this source matters",[78,85,86],{},"This is a direct human comparison for one diagnosed condition: denture stomatitis classified as Newton type I or II. It reports absolute clinical counts and salivary Candida counts after two weeks. The small analyzed sample and missing data make the comparison uncertain. The study did not examine general oral thrush or broad Candida symptoms, and it did not measure biofilm or test a biofilm-disrupting product.",[74,88,90],{"section-key":12,"title":89},"Study and population",[78,91,92],{},"Lee Muñoz and colleagues recruited through oral-health programs in one municipality near the University of Chile Faculty of Dentistry from September 2021 to March 2022. They invited 621 older adults; 43 self-reliant volunteers aged 60 or older were randomized. Participants were healthy or had medically controlled chronic conditions, used removable acrylic or metal-base dentures, and had clinical Newton type I or II denture stomatitis. The analyzed group was 33 people: 15 assigned to CHX and 18 to VCO; 32 were women and one was a man. People with Newton type III disease, severe dependence or institutionalization, cognitive impairment, recent antibiotic or antifungal use, or allergy or intolerance to either rinse were excluded.",[74,94,96],{"section-key":13,"title":95},"What was tested",[78,97,98],{},"For 14 days, the CHX group rinsed with 15 mL of commercially obtained 0.12% chlorhexidine for five minutes twice daily. The VCO group used about 5 g (one teaspoon) of virgin coconut oil for five minutes twice daily. Participants removed their dentures, were told not to swallow the rinse, and received denture-hygiene instructions. Dentists assessed Newton severity and collected unstimulated saliva at baseline (T0), day 7 (T1), and day 14 (T2); the abstract calls the final assessment day 15. Saliva was cultured, and colonies judged compatible with Candida were counted as CFU/mL. Species-level identification and biofilm measurement were not reported.",[74,100,102,105,108,111],{"section-key":14,"title":101},"Results",[78,103,104],{},"Of 43 randomized participants (21 CHX and 22 VCO), 33 were analyzed (15 CHX and 18 VCO). The authors said the 10 people who did not complete treatment were not included in the study analysis. In the T1 severity tables, counts total 13 for CHX and 16 for VCO; the paper does not explain which participants missed that visit.",[78,106,107],{},"At baseline, no analyzed participant in either group was classified as healthy: 0/15 in CHX and 0/18 in VCO. By T2, the counts classified as healthy were 5/15 (33%) with CHX and 9/18 (50%) with VCO. The paper reported within-arm severity changes from T0 to T2 for CHX (p=.014) and VCO (p=.002). It also reported a slight association between treatment and remission without a statistically significant difference. The within-group tests do not establish that one treatment outperformed the other.",[78,109,110],{},"Median salivary Candida-compatible counts were 261.5 CFU/mL at T0 and 779 at T2 with CHX (ranges 0–58,400 and 0–21,640), and 631 at T0 and 50 at T2 with VCO (ranges 0–52,400 and 0–81,800). Neither T0-to-T2 change was statistically significant (CHX p=.092; VCO p=.974). Counts came from saliva cultures; the paper did not report species-level identification or measure Candida on the palate or denture surface.",[78,112,113],{},"The article did not report how adverse events were assessed or provide adverse-event counts. It therefore does not show that harms were absent.",[74,115,117],{"section-key":15,"title":116},"Applicability",[78,118,119],{},"These findings apply to the analyzed group of self-reliant adults aged 60 or older with removable dentures and clinically classified Newton type I or II denture stomatitis who received VCO or CHX with denture-hygiene instructions. They do not establish how either rinse compares for people with more severe disease, younger people, or people who were excluded from the trial. Denture stomatitis is not interchangeable with general oral thrush. The results do not apply to Candida symptoms elsewhere, broad Candida explanations, or products claimed to disrupt biofilms; biofilm was not measured.",[74,121,123],{"section-key":16,"title":122},"Limitations",[78,124,125],{},"Only 33 of 43 randomized participants were analyzed, despite the authors describing the analysis as intention-to-treat; the paper does not provide arm-specific reasons for non-completion or explain missing outcomes. The T1 severity tables include 13 CHX and 16 VCO participants, without identifying the missing visits. The final sample was small, recruited through one municipality, and included 32 women and one man. The authors reported a slight association between treatment and remission without a statistically significant difference; they gave no confidence interval for that comparison. The within-group severity tests do not establish VCO superiority or noninferiority to CHX. Salivary colony counts were not species-identified and were not a measure of Candida on the denture or palate. Neither group had a significant T0-to-T2 decrease in these counts. Adverse events were not reported, so their absence cannot be inferred. The Methods section calls the final examination day 14, whereas the abstract calls it day 15. Although the authors call the study triple-blind, they do not explain how masking worked for the distinguishable rinses.",[74,127,129],{"section-key":17,"title":128},"Contribution to the current conclusion",[78,130,131],{},"Contextual contribution. This trial adds a small human comparison of VCO and CHX for diagnosed Newton type I or II denture stomatitis. Its end-of-study clinical counts and within-arm changes do not establish a between-arm advantage, and neither group had a significant baseline-to-end decrease in salivary Candida counts. Attrition, unexplained T1 data, and unreported adverse events limit interpretation. The study does not measure biofilm or test broad Candida claims, so it does not change the linked evidence map's conclusion or practical guidance.",[74,133,135],{"section-key":18,"title":134},"Practical change or no change",[78,136,137],{},"No practical change. The trial does not support recommending coconut oil, changing care for general oral thrush, or using a consumer product to address a claimed Candida biofilm. The article reports no adverse-event data and does not establish which rinse had fewer harms.",[74,139,141],{"section-key":19,"title":140},"Funding and conflicts",[78,142,143],{},"The study was funded by grant FONIS SA19I0025 from the Chilean National Research and Development Agency (ANID), Government of Chile. The authors declared no competing interests.",[74,145,147],{"section-key":20,"title":146},"Source",[78,148,149,156,157,161],{},[150,151,155],"a",{"href":152,"rel":153},"https://pmc.ncbi.nlm.nih.gov/articles/PMC10225286/",[154],"nofollow","Read the original article"," (Lee Muñoz et al., ",[158,159,160],"em",{},"Clinical Oral Investigations",". 2023;27(7):3713–3720; published online May 29, 2023).",{"title":163,"searchDepth":164,"depth":164,"links":165},"",2,[],{"sources":167,"claims":173,"safety":174},[168],{"sourceId":27,"title":169,"canonicalId":170,"canonicalUrl":171,"publisher":160,"sourceType":172,"publicationDate":36,"lastChecked":24},"Medium-chain fatty acids as an alternative treatment for denture stomatitis in older people","PMID:37247088; DOI:10.1007/s00784-023-04987-3","https://link.springer.com/article/10.1007/s00784-023-04987-3","randomized-trial",[],[],[176,179,182],{"rel":177,"hreflang":6,"href":178},"alternate","https://candipedia.org/en/research/coconut-oil-denture-stomatitis-trial-2023/",{"rel":177,"hreflang":180,"href":181},"pl-PL","https://candipedia.org/pl/research/olej-kokosowy-stomatopatia-protetyczna-badanie-2023/",{"rel":177,"hreflang":183,"href":178},"x-default",1794951393372]